Action Potential Venture Capital (APVC) is GSK's bioelectronic medicines venture fund. APVC is focused on the next generation of peripheral neuromodulation medical devices, and invests in companies and technologies that enable the future of targeted and adaptive bioelectronics.
Location: United States, California, Palo Alto
Employees: 1-10
Founded date: 2013
Investment Type: Venture Capital
Investment Stage: Series D
Portfolio 13
Date | Name | Website | Total Raised | Location |
26.01.2023 | Onc.AI | onc.ai | $6M | United Sta... |
29.06.2022 | Vivistim® | vivistim.c... | - | United Sta... |
29.06.2022 | MicroTrans... | microtrans... | $134.89M | United Sta... |
10.06.2022 | Cala Healt... | calatrio.c... | - | United Sta... |
21.12.2021 | Alpheus Me... | alpheusmed... | $16M | United Sta... |
31.05.2017 | Saluda Med... | saludamedi... | $275M | Australia,... |
- | Neuspera M... | neuspera.c... | $117M | United Sta... |
- | Cala Healt... | calahealth... | $145M | United Sta... |
- | Exo | exo.inc | $220M | United Sta... |
- | SetPoint M... | setpointme... | $187M | United Sta... |
Show more
Persons 1
Date | First Name | Last Name | Title | |||
- | Ali | Kight | - | linkedin.c... | - | - |
Mentions in press and media 1
Date | Title | Description | Source |
31.05.2017 | Australia: Saluda Medical raises $40m Series D investment le... | Premium Saluda Medical Pty Limited, a medical device company developing a platform of closed-loop n... | dealstreet... |